LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by DF Dent & Co. Inc.

DF Dent & Co. Inc. lowered its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 26.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 190,362 shares of the medical instruments supplier’s stock after selling 68,405 shares during the period. DF Dent & Co. Inc. owned about 0.85% of LeMaitre Vascular worth $17,540,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Smartleaf Asset Management LLC increased its holdings in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 293 shares during the period. CBIZ Investment Advisory Services LLC grew its position in LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV increased its stake in LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after purchasing an additional 410 shares during the period. Huntington National Bank raised its holdings in shares of LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 455 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of LeMaitre Vascular during the fourth quarter worth about $150,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Trading Up 1.7 %

Shares of LeMaitre Vascular stock opened at $86.62 on Thursday. The company has a 50-day moving average of $92.25 and a two-hundred day moving average of $94.31. LeMaitre Vascular, Inc. has a 12-month low of $62.39 and a 12-month high of $109.58. The stock has a market cap of $1.95 billion, a PE ratio of 47.33, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. The firm had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were given a $0.20 dividend. The ex-dividend date was Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a dividend yield of 0.92%. LeMaitre Vascular’s payout ratio is currently 41.24%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company’s stock, valued at $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on the company. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Lake Street Capital raised their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.